Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12792431rdf:typepubmed:Citationlld:pubmed
pubmed-article:12792431lifeskim:mentionsumls-concept:C0024501lld:lifeskim
pubmed-article:12792431lifeskim:mentionsumls-concept:C0010346lld:lifeskim
pubmed-article:12792431lifeskim:mentionsumls-concept:C0043240lld:lifeskim
pubmed-article:12792431lifeskim:mentionsumls-concept:C0021081lld:lifeskim
pubmed-article:12792431lifeskim:mentionsumls-concept:C0332161lld:lifeskim
pubmed-article:12792431lifeskim:mentionsumls-concept:C0574032lld:lifeskim
pubmed-article:12792431lifeskim:mentionsumls-concept:C0666743lld:lifeskim
pubmed-article:12792431lifeskim:mentionsumls-concept:C0596545lld:lifeskim
pubmed-article:12792431lifeskim:mentionsumls-concept:C1521828lld:lifeskim
pubmed-article:12792431lifeskim:mentionsumls-concept:C1524072lld:lifeskim
pubmed-article:12792431lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:12792431lifeskim:mentionsumls-concept:C0205099lld:lifeskim
pubmed-article:12792431lifeskim:mentionsumls-concept:C0205171lld:lifeskim
pubmed-article:12792431pubmed:issue5lld:pubmed
pubmed-article:12792431pubmed:dateCreated2003-6-6lld:pubmed
pubmed-article:12792431pubmed:abstractTextInfliximab (anti-TNF alpha) has been used for the treatment of fistulizing Crohn's disease with variable efficacy. The aim of this study was to evaluate the efficacy of infliximab combined with selective seton drainage in the healing of fistulizing anorectal Crohn's disease.lld:pubmed
pubmed-article:12792431pubmed:languageenglld:pubmed
pubmed-article:12792431pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12792431pubmed:citationSubsetIMlld:pubmed
pubmed-article:12792431pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12792431pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12792431pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12792431pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12792431pubmed:statusMEDLINElld:pubmed
pubmed-article:12792431pubmed:monthMaylld:pubmed
pubmed-article:12792431pubmed:issn0012-3706lld:pubmed
pubmed-article:12792431pubmed:authorpubmed-author:MacLeanAnthon...lld:pubmed
pubmed-article:12792431pubmed:authorpubmed-author:PanaccioneRem...lld:pubmed
pubmed-article:12792431pubmed:authorpubmed-author:BuieW...lld:pubmed
pubmed-article:12792431pubmed:authorpubmed-author:TopstadDawnel...lld:pubmed
pubmed-article:12792431pubmed:authorpubmed-author:HeineJohn AJAlld:pubmed
pubmed-article:12792431pubmed:authorpubmed-author:JohnsonDougla...lld:pubmed
pubmed-article:12792431pubmed:issnTypePrintlld:pubmed
pubmed-article:12792431pubmed:volume46lld:pubmed
pubmed-article:12792431pubmed:ownerNLMlld:pubmed
pubmed-article:12792431pubmed:authorsCompleteYlld:pubmed
pubmed-article:12792431pubmed:pagination577-83lld:pubmed
pubmed-article:12792431pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:12792431pubmed:meshHeadingpubmed-meshheading:12792431...lld:pubmed
pubmed-article:12792431pubmed:meshHeadingpubmed-meshheading:12792431...lld:pubmed
pubmed-article:12792431pubmed:meshHeadingpubmed-meshheading:12792431...lld:pubmed
pubmed-article:12792431pubmed:meshHeadingpubmed-meshheading:12792431...lld:pubmed
pubmed-article:12792431pubmed:meshHeadingpubmed-meshheading:12792431...lld:pubmed
pubmed-article:12792431pubmed:meshHeadingpubmed-meshheading:12792431...lld:pubmed
pubmed-article:12792431pubmed:meshHeadingpubmed-meshheading:12792431...lld:pubmed
pubmed-article:12792431pubmed:meshHeadingpubmed-meshheading:12792431...lld:pubmed
pubmed-article:12792431pubmed:meshHeadingpubmed-meshheading:12792431...lld:pubmed
pubmed-article:12792431pubmed:meshHeadingpubmed-meshheading:12792431...lld:pubmed
pubmed-article:12792431pubmed:meshHeadingpubmed-meshheading:12792431...lld:pubmed
pubmed-article:12792431pubmed:meshHeadingpubmed-meshheading:12792431...lld:pubmed
pubmed-article:12792431pubmed:meshHeadingpubmed-meshheading:12792431...lld:pubmed
pubmed-article:12792431pubmed:meshHeadingpubmed-meshheading:12792431...lld:pubmed
pubmed-article:12792431pubmed:meshHeadingpubmed-meshheading:12792431...lld:pubmed
pubmed-article:12792431pubmed:meshHeadingpubmed-meshheading:12792431...lld:pubmed
pubmed-article:12792431pubmed:meshHeadingpubmed-meshheading:12792431...lld:pubmed
pubmed-article:12792431pubmed:meshHeadingpubmed-meshheading:12792431...lld:pubmed
pubmed-article:12792431pubmed:year2003lld:pubmed
pubmed-article:12792431pubmed:articleTitleCombined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience.lld:pubmed
pubmed-article:12792431pubmed:affiliationDepartment of Surgery, Foothills Hospital, University of Calgary, Calgary, Alberta, Canada.lld:pubmed
pubmed-article:12792431pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12792431pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12792431lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12792431lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12792431lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12792431lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12792431lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12792431lld:pubmed